August 23, 2018 by B. Douglas Hoey
Doug Hoey, National Community Pharmacists Association, pharmacy benefit managers
Issue 08-13-2018, Opinion
NEW YORK — Physicians Robin Warren and Barry Marshall were practically laughed out of health care in 1982 when they suggested that a type of bacteria might be causing stomach ulcers. It took more than a decade before their theory that treating ulcers with antibiotics to kill H. pylori bacteria was validated, and it radically
January 15, 2018 by Chain Drug Review
B. Douglas Hoey, Center for Medicare & Medicaid Innovation, Centers for Medicare & Medicaid Services, CMS-4182-P Medicare Program, community pharmacies, DIR fees, Medicare Part D, National Community Pharmacists Association, NCPA, PBM business model, pharmacy benefit managers
2018, Issue 01-15-2018, Issues, Opinion
WASHINGTON — In recent testimony before the House of Representatives Energy and Commerce Subcommittee on Health, National Community Pharmacists Association (NCPA) chief executive officer B. Douglas Hoey said pharmacists can drive better health outcomes and reduce costs, but first pharmacy benefit managers’ problematic business practices must be addressed through legislative and regulatory channels. As an
October 17, 2017 by Chain Drug Review
Cost of Prescription Drugs: How the Delivery System Affects What Patients Pay, DIR fees, H.R. 1038, Improving Transparency and Accuracy in Medicare Part D Drug Spending Act, Mark Merritt, National Community Pharmacists Association, Pharmaceutical Care Management Association, pharmacy benefit managers, prescription drug costs, S. 413, Senate HELP Committee, Senior Care Pharmacy Coalition
Featured Articles, Leading Headlines, Pharmacy, Retail News
WASHINGTON — Pharmacy benefit managers are a key focus of debate about elevated drug pricing that has come before a U.S. Senate committee. The National Community Pharmacists Association (NCPA) and the Senior Care Pharmacy Coalition (SCPC) called for PBM reform in written testimony submitted to a Senate Health, Education, Labor and Pensions (HELP) Committee hearing
April 25, 2017 by CDR Blog and Chain Drug Review
B. Douglas Hoey, DrugBenefitSolutions, independent community pharmacies, Mark Merritt, National Community Pharmacists Association, NCPA, NCPA's Congressional Pharmacy Fly-In, PBMs, PCMA, Pharmaceutical Care Management Association, pharmacy benefit managers, The PBM Story
CDR Blog
A lobbying event in Washington has triggered salvoes between two combatants: independent community pharmacies and pharmacy benefit managers. The National Community Pharmacists Association is holding its Congressional Pharmacy Fly-In advocacy drive this week, where it will also release “The PBM Story: What They Say, What They Do, and What Can Be Done About It,” offered
March 16, 2017 by Chain Drug Review
B. Douglas Hoey, C-THRU, Creating Transparency to Have Drug Rebates Unlocked Act, National Community Pharmacists Association, NCPA, PBMs, PCMA, Pharmaceutical Care Management Association, pharmacy benefit managers, prescription drug pricing, Ron Wyden
Featured Articles, Leading Headlines, Pharmacy, Retail News
WASHINGTON — Sen. Ron Wyden (D., Ore.) has introduced the Creating Transparency to Have Drug Rebates Unlocked Act (C-THRU), aimed at bringing more visibility into prescription drug pricing by pharmacy benefit managers. The C-THRU legislation, initiated Wednesday in the Senate Finance Committee, would require PBMs serving Medicare Part D plans to disclose the aggregate rebates
March 7, 2017 by Chain Drug Review
Austin Scott, Brian Babin, Buddy Carter, Dave Loebsack, Doug Collins, H.R. 1316, John Duncan, Mark Merritt, National Community Pharmacists Association, NCPA, PBMs, PCMA, Pharmaceutical Care Management Association, pharmacy benefit managers, prescription drug costs, Prescription Drug Price Transparency Act, video
Videos
A half-dozen congressmen pointed a finger at pharmacy benefit managers (PBMs) on the floor of the House of Representatives last week in an hour of comments on the high cost of prescriptions drugs, the National Community Pharmacists Association (NCPA) said in its Executive Update e-newsletter. In the session, Reps. Doug Collins (R., Ga.), Brian Babin
January 12, 2017 by CDR Blog and Chain Drug Review
B. Douglas Hoey, Donald Trump, drug industry, drug pricing, National Community Pharmacists Association, NCPA, PBMs, pharmaceutical industry, pharmacy benefit managers, prescription drug prices
CDR Blog
Donald Trump briefly touched on the pharmaceutical industry in his first major press conference since being elected president. In the news conference yesterday at Trump Tower in Manhattan, Trump talked about drug companies relocating overseas and referred to the rising cost of pharmaceuticals. “We’ve got to get our drug industry back,” Trump said after discussing
July 21, 2015 by Chain Drug Review and Chain Drug Review
B. Douglas Hoey, below-cost reimbursements, generic drugs, H.R. 244, independent community pharmacies, MAC Transparency Act, National Community Pharmacists Association, NCPA, PBM reimbursement, pharmacy benefit managers
Leading Headlines, Pharmacy, Retail News
ALEXANDRIA, Va. — The National Community Pharmacists Association said it has compiled evidence that underscores the need for federal sunshine legislation to provide more insight into below-cost reimbursements from pharmacy benefit managers that don’t keep pace with rising market costs for generic drugs. NCPA said Monday that it recently asked members for examples illustrating the
January 5, 2015 by Geoff Walden and Chain Drug Review
B. Douglas Hoey, Centers for Medicare and Medicaid Services, H.R. 4577, Mark Merritt, Medicare Part D drug plans, National Community Pharmacists Association, Pharmaceutical Care Management Association, pharmacy benefit managers, pharmacy networks, preferred pharmacies
2015, Issue 01-05-2015, News, Pharmacy
WASHINGTON — Preferred pharmacies for Medicare Part D drug plans are more accessible in suburbs and rural areas than in cities, a study by the Centers for Medicare and Medicaid Services (CMS) has found. “While we appreciate the importance of providing lower costs to beneficiaries, these findings reinforce CMS’ concern that plans are offering access